CD177+ neutrophils exert both bactericidal activity and barrier-protective effects at sites of mucosal inflammation in IBD, while also modulating the release of inflammatory mediators that are strongly associated with disease severity in affected patients. Here, CD177 is linked to inflammatory bowel disease.